Day: March 10, 2022

– Continues to Execute on Turnaround Strategy, Reports Sixth Consecutive Quarter of Revenue Growth – – Completes Strategic Entry into Cannabis Sector; Expects to Launch Portfolio by End of First Quarter – SEATTLE, March 10, 2022 (GLOBE NEWSWIRE) — Jones Soda Co. (CSE: JSDA, OTCQB: JSDA) (“Jones Soda” or the “Company”), the original craft soda company known for its unconventional flavors and user-designed label artwork, announced its financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights vs. Year-Ago QuarterRevenue increased 18% to $2.9 million compared to $2.5 million. Gross profit as a percentage of revenue increased 260 basis points to 26.5% compared to 23.9%. Net loss was $1.3 million, or $(0.02) per share, compared to a net loss of $0.9 million, or $(0.01)...

Fourth quarter revenue totaled $96.5 million, representing an increase of 56% year-over-year; fiscal 2022 revenue totaled $320.8 million, representing an increase of 51% year-over-year. Trailing four quarter average Net Dollar Revenue Retention rate was 131% at the end of the fourth quarter fiscal 2022, up from 123% in the fourth quarter of fiscal 2021. Fourth quarter total GAAP RPO totaled $428.8 million, representing an increase of 62% year-over-year; fourth quarter current GAAP RPO totaled $268.9 million, representing an increase of 62% year-over-year. Fourth quarter total non-GAAP RPO totaled $452.2 million, representing an increase of 58% year-over-year; fourth quarter current non-GAAP RPO totaled $289.2 million, representing an increase of 55% year-over-year.SAN FRANCISCO, March 10, 2022 (GLOBE NEWSWIRE) — HashiCorp, Inc....

LYNNWOOD, Wash., March 10, 2022 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today reported results for the fourth quarter and year ended January 29, 2022. Net sales for the fourth quarter ended January 29, 2022 (13 weeks) increased 4.6% to $346.7 million from $331.5 million in the fourth quarter ended January 30, 2021 (13 weeks). Compared to the fourth quarter ended February 1, 2020 (13 weeks), fourth quarter 2021 net sales increased 5.5%. Net income in the fourth quarter of fiscal 2021 was $38.2 million, or $1.70 per diluted share, compared to net income of $42.8 million, or $1.68 per diluted share, in the fourth quarter of the prior fiscal year. Net income for the fourth quarter of 2019 was $37.9 million, or $1.48 per diluted...

IRVINE, Calif., March 10, 2022 (GLOBE NEWSWIRE) — Viant Technology Inc. (NASDAQ: DSP), a leading people-based advertising software company, today reported financial results for its fourth quarter and full year ended December 31, 2021. “Our fourth quarter results, which beat our revenue and profitability guidance, concluded an incredible year for Viant. We greatly exceeded our expectations on all key financial metrics for the year and delivered against every aspect of our business strategy that we outlined in our February 2021 IPO, further proving out Viant’s business model and technology,” said Tim Vanderhook, co-founder and CEO of Viant. “We expect advertiser spend across our platform to further accelerate in 2022, and we are setting long term goals for revenue of at least $500 million and adjusted EBITDA as a percentage of contribution...

COSTA MESA, Calif., March 10, 2022 (GLOBE NEWSWIRE) — El Pollo Loco Holdings, Inc. (Nasdaq: LOCO) today announced financial results for the 13-week period ended December 29, 2021. Highlights for the fourth quarter ended December 29, 2021 compared to the fourth quarter ended December 30, 2020 were as follows:Total revenue was $109.0 million compared to $110.3 million. System-wide comparable restaurant sales(1) increased 11.0%. Income from operations was $8.4 million compared to $8.2 million. Restaurant contribution(1) was $14.7 million, or 15.7% of company-operated restaurant revenue, compared to $15.3 million, or 15.8% of company-operated restaurant revenue. Net income was $6.2 million, or $0.17 per diluted share, compared to net income of $5.5 million, or $0.15 per diluted share. Pro forma net income(1) was $6.1 million, or $0.17 per...

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) —  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021. “Our expanded strategy and pipeline progress in 2021 have positioned us to reach a number of important milestones in 2022 with both our core inhibitor portfolio and our research programs beyond core inhibition and HBV,” said John McHutchison, AO, MD, chief executive officer and president of Assembly Bio. “The Phase 2 triple combination studies evaluating our lead investigational core inhibitor candidate, vebicorvir (VBR), plus standard-of care NrtI with other complementary mechanisms...

Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., March 10, 2022 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. “We continue to advance three clinical programs for novel product candidates targeting CD73, the adenosine 2A receptor, and ITK, which are involved in immune response to cancers and other diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “We have established sound scientific foundations for our product candidates, which give us confidence as we initiate mid-stage clinical trials in front-line treatment of lung cancer...

CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos’ proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient cash balance to fund planned operations into the first half 2024 SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics,...